Literature DB >> 22846254

Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience.

Matthias Heuer1, Gernot M Kaiser, Alisan Kahraman, Mark Banysch, Fuat H Saner, Zoltan Mathé, Guido Gerken, Andreas Paul, Ali Canbay, Jürgen W Treckmann.   

Abstract

BACKGROUND/AIMS: Non-alcoholic fatty liver disease (NAFLD) with its progressive form nonalcoholic steatohepatitis (NASH) is the most common chronic liver disease in western countries which is associated with end-stage liver disease and hepatocellular carcinoma (HCC). This entity is a consistently increasing indication for transplantation. However, data about postsurgery outcome and complications are still limited. PATIENTS AND METHODS: Records of 432 consecutive transplanted patients between October 2007 and January 2011 were investigated retrospectively. Forty transplants were performed due to NASH-induced cirrhosis. Perioperative courses and short- and long-term outcomes were analyzed.
RESULTS: The NAFLD population consisted of 16 women and 24 men with a mean age of 55 years. The median MELD score was 27 at the time of liver transplantion. BMI before surgery ranged from 21 to 45 (mean 31). Sixteen of the initial 40 patients are still alive. Patients with sustained obesity and features of the metabolic syndrome had a worse 1-year mortality rate of 42%.
CONCLUSIONS: A significant number of liver transplantations in our center was performed due to NASH; transplantation in this cohort was associated with high mortality and postoperative complications, most likely due to associated obesity and diabetes. Weight reduction prior to surgery may lead to a better outcome.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22846254     DOI: 10.1159/000339344

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  18 in total

Review 1.  Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances.

Authors:  Adnan Said
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

2.  Ghrelin: a new treatment for non-alcoholic fatty liver disease?

Authors:  Patric J D Delhanty; Aart J van der Lely
Journal:  Endocrine       Date:  2012-09-20       Impact factor: 3.633

Review 3.  Nonalcoholic fatty liver disease and cardiovascular disease.

Authors:  Hong Liu; Hong-Yun Lu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

4.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  Diabetologia       Date:  2016-06       Impact factor: 10.122

5.  Metabolic disorders, non-alcoholic fatty liver disease and major liver resection: an underestimated perioperative risk.

Authors:  Alban Zarzavadjian Le Bian; Renato Costi; Vassilis Constantinides; Claude Smadja
Journal:  J Gastrointest Surg       Date:  2012-10-09       Impact factor: 3.452

6.  Surgical outcomes in patients with hepatocellular carcinoma associated with metabolic syndrome.

Authors:  Naoki Yoshida; Tadatoshi Takayama; Yutaka Midorikawa; Tokio Higaki; Hisashi Nakayama; Masamichi Moriguchi; Shingo Tsuji
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

Review 7.  Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective.

Authors:  Naga S Samji; Rajanshu Verma; Sanjaya K Satapathy
Journal:  J Clin Exp Hepatol       Date:  2019-05-16

Review 8.  Recent advances in the development of farnesoid X receptor agonists.

Authors:  Ahmad H Ali; Elizabeth J Carey; Keith D Lindor
Journal:  Ann Transl Med       Date:  2015-01

9.  Oil Red O-assessed macrosteatosis in liver transplant donor biopsies predicts ischemia-reperfusion injury and clinical outcome.

Authors:  Henning Reis; Patricia T Peterek; Jeremias Wohlschlaeger; Gernot M Kaiser; Zoltan Mathe; Benjamin Juntermanns; Georgios C Sotiropoulos; Ulrich Beckhove; Ali Canbay; Ulrike Wirges; Andre Scherag; Juergen-Walter Treckmann; Andreas Paul; Hideo Andreas Baba
Journal:  Virchows Arch       Date:  2013-12-03       Impact factor: 4.064

10.  Pediatric Nonalcoholic Fatty Liver Disease: A Report from the Expert Committee on Nonalcoholic Fatty Liver Disease (ECON).

Authors:  Rohit Kohli; Shikha Sunduram; Marialena Mouzaki; Sabina Ali; Pushpa Sathya; Stephanie Abrams; Stavra A Xanthakos; Miriam Vos; Jeffrey B Schwimmer
Journal:  J Pediatr       Date:  2016-01-01       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.